Zhengye Biotechnology Holding Limited Class A (ZYBT)
NASDAQ: ZYBTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ZYBT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $70.14M
- EPS (TTM)
- -$0.20
- Dividend yield
- None
- 52-week range
- 0.616 – 8.01
- Day range
- 1.45 – 1.51
- Volume / Avg
- 10.50K / 569.22K
- Beta
- —
- Shares outstanding
- 47.39M
52-week range
ZYBT stock today
Shares of Zhengye Biotechnology (ZYBT) finished lower on Nov 20 at $1.48, a drop of 2.63% or $0.04 per share, versus the S&P 500's 3.70% decline. Trading was light, with 10.50K shares changing hands, about 2% of the average daily volume. Shares are 81.5% below their 52-week high of $8.01, set on Jul 20, 2026 and 140.3% above the 52-week low of $0.616, near the bottom of the past year's range.
ZYBT is up 28.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 30.8%. Zhengye Biotechnology has posted a net loss over the last twelve months (EPS of -$0.20), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Zhengye Biotechnology
Company profileZhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Songlin Song
- Headquarters
- Jilin
- Employees
- 269
- IPO year
- 2025
- Website
- jlzybio.com
Financial highlights
Full financialsIn fiscal 2025, Zhengye Biotechnology generated $16.6 million in revenue, down 34.8% from fiscal 2024, the first decline in the 2 years shown. Zhengye Biotechnology reported a net loss of $10.0 million, compared with net income of $1.6 million a year earlier. Gross margin was 20.5% (down from 49.0%) and operating margin -60.6%.
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | $16.64M | $25.53M |
| Growth | -34.83% | — |
| Net income | $-9.98M | $1.55M |
| EPS (diluted) | — | $0.03 |
ZYBT news
All ZYBT newsZhengye Biotechnology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| COYACoya Therapeutics Inc. | 2.95 | -1.01% | $69.20M | vs ZYBT |
| MAIAMAIA Biotechnology Inc. | 1.11 | -2.63% | $68.54M | vs ZYBT |
| CINGCingulate Inc. | 4.51 | -14.26% | $67.48M | vs ZYBT |
| MNOVMedicinova Inc | 1.31 | +3.15% | $67.11M | vs ZYBT |
| PLYXPolaryx Therapeutics Inc. | 1.33 | -11.92% | $66.30M | vs ZYBT |
| PMVPPMV Pharmaceuticals Inc. | 0.876 | -33.13% | $66.17M | vs ZYBT |
| GOSSGossamer Bio Inc. | 10.72 | -4.54% | $65.57M | vs ZYBT |
| FBIOFortress Biotech Inc. | 1.90 | +7.34% | $64.11M | vs ZYBT |
Indexes, lists and sector
Zhengye Biotechnology stock FAQ
What is Zhengye Biotechnology's stock price today?
ZYBT last traded at $1.48 as of Nov 20, 4:00 PM EST, down 2.63% on the day. Prices are delayed at least 15 minutes.
Who is Zhengye Biotechnology's CEO?
Mr. Songlin Song is the chief executive officer of Zhengye Biotechnology Holding Limited Class A, which has about 269 employees.
What is the ZYBT 52-week high?
The 52-week high for ZYBT is $8.01 and the 52-week low is $0.616. The stock is currently 81.5% below its high.